Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients.

Jeff brings nearly 30 years of experience in the pharmaceutical and CRO industry, most recently as CEO of another therapeutically focused CRO, where he has distinguished himself through his exceptional leadership, strategic vision, and ability to innovate. His expertise spans global operations, growth management, and fostering a collaborative and high-performing corporate culture. Jeff’s strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles.

Jeff is well-equipped to lead Innovaderm into its next phase of growth and innovation. Innovaderm is excited to add therapeutic expertise in rheumatology in addition to our world class dermatology research services, further expanding our capabilities and dedication to advancing medical knowledge and new therapies as a dual-focused CRO. Mr. Smith’s proven track record in organizational expansion and achieving meaningful and impactful results will be invaluable in driving these efforts forward.

“I am truly honored to join Innovaderm as CEO and collaborate with such a dedicated and talented team. Together, we are poised to work together with our sponsors to drive innovation in clinical research, making meaningful advancements in dermatology and rheumatology that will directly benefit patients and improve their quality of life.” Jeff Smith

Dr. Bissonnette, the founder of Innovaderm, remains as Executive Chairman, ensuring the CRO’s continuity and stability. His ongoing leadership will continue to guide Innovaderm’s mission to advance clinical research and improve patient outcomes. “I am confident Jeff Smith’s leadership will drive Innovaderm to new heights,” said Dr. Robert Bissonnette.

For more information about our dermatology and rheumatology resources please visit: https://innovaderm.com/

Innovaderm Research Inc.

Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials. With over 25 years of globally recognized expertise in dermatology and clinical operations, an extensive and continually expanding network of clinicians and sites, and a dedicated research clinic, Innovaderm offers a highly informed, focused, and comprehensive approach to addressing niche clinical needs in dermatology and rheumatology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250203738867/en/

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

Logo

Tags

More Like This

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

Innovaderm Research Appoints Ina Zschocke as New Executive Vice President, European Operations and Strategy

Innovaderm, Recognized by Clinical Leaders CRO Leadership Awards for the 4th Consecutive Year

Specialist CRO Welcomes Dr Juan Gabriel Ovalles Bonilla as Medical Rheumatology Lead

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

François Ravenelle, PhD Appointed President and CEO of Innospera Pharma to Lead Next Phase of Growth

Indero Marks 40th Study Live with Veeva RTSM

Comac Medical Announces New Leadership Appointments and International Expansion